Market Research Report
U.S. Direct-to-Consumer Genetic Testing Market Size By Test Type, By Technology, Industry Analysis Report, Application Potential, Competitive Market Share & Forecast, 2019 - 2025
|U.S. Direct-to-Consumer Genetic Testing Market Size By Test Type, By Technology, Industry Analysis Report, Application Potential, Competitive Market Share & Forecast, 2019 - 2025|
Published: September 24, 2019
Global Market Insights Inc.
Content info: 56 Pages
Delivery time: 2-3 business days
U.S. Direct-to-Consumer Genetic Testing Market Size By Test Type (Carrier Testing, Predictive Testing, Ancestry & Relationship Testing, Nutrigenomics Testing), By Technology (Targeted Analysis, Single Nucleotide Polymorphism (SNP) Chips, Whole Genome Sequencing (WGS)), Industry Analysis Report, Application Potential, Competitive Market Share & Forecast, 2019 - 2025.
U.S. Direct-To-Consumer Genetic Testing Market is expected to exceed USD 850 million by 2025. Increasing public awareness pertaining to availability of DTC genetic testing kits will be a high impact rendering factor for the U.S. DTC genetic testing market growth.
Some major findings of the U.S. direct-to-consumer genetic testing market report include:
Rising incidence of genetic diseases will accelerate demand for direct-to-consumer genetic testing kits over the forecast period. Genetic disorders such as achondroplasia, Parkinson's and Alzheimer's diseases are amongst the major ailments that cause adverse effect on an individual's life. Direct access to genetic tests allows patients to know the probability of acquiring such disorders that has reduced the mortality rates. As a result, DTC genetic testing kits have crucial role in recognizing the genetic alterations, thereby escalating its demand in coming years.
Growing demand for personalized DTC genetic testing services will be a high impact rendering factor for U.S. direct-to-consumer genetic testing market. DTC tests are user friendly and provide accurate results. Industry players focus on providing technologically advanced solutions that rises its adoption. For instance, 23andMe manufactures DTC test that utilizes genotype testing technology that provides data on health, carrier status, behavioral attributes for studying drug interactions. Therefore, growing availability of such advanced tests for detection of diseases will spur the industry growth. However, high cost of these kits may hamper the U.S. direct-to-consumer genetic testing market growth to some extent.
Predictive testing segment is anticipated to witness over 16% CAGR throughout the analysis timeframe. Increasing prevalence of genetic diseases will prove beneficial for the U.S. direct-to-genetic testing market growth. Predictive testing helps in detecting the disease before the onset of the disease that in turn will help in reducing the morbidity and mortality rate. Aforementioned factors will escalate the segment growth in near future.
Single nucleotide polymorphism (SNP) chips segment valued for more than USD 140 million in 2018 and it will grow substantially over the forecast period. SNP chips helps in analyzing gene sequences at a particular resolution that reveals detailed analysis regarding defective genes. SNP chips specifically detect changes at molecular level that further increases the efficiency of tests. Therefore, SNP technology is highly preferred during drug discovery process that should augment the segment growth.
Companies are investing in operational activities to offer reliable DTC tests to end-users. Moreover, they are also adopting numerous strategic initiatives such as acquisitions, mergers, product launches, geographical expansions and collaborations to acquire significant market share, sustain the competition and gain competitive advantage over others. For instance, in July 2018, 23andme announced collaboration with GlaxoSmithKline (GSK) company. Collaboration will enable the company to discover therapeutics to treat genetic diseases that enables company to expand its share in the DTC genetic testing market.